Bayer builds on NAT (nucleic acid diagnostic) with $61.4 million Visible Genetics deal
This article was originally published in Clinica
Bayer Diagnostics is to significantly expand its nucleic acid diagnostic (NAT) business with its planned $61.4m acquisition of tiny pharmacogenomics company Visible Genetics. In the cash deal, Bayer is offering $1.50 per Visible Genetics' share and its series A preferred shares at par plus accrued dividends.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.